Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendations.

OBJECTIVE To examine prescribing practices in the use of biologic and nonbiologic disease-modifying antirheumatic drugs (DMARDs) to treat patients with rheumatoid arthritis (RA), before and after publication of the American College of Rheumatology (ACR) treatment recommendations. METHODS Biologics-naive RA patients under the care of a rheumatologist in the US were identified from the Consortium of Rheumatology Researchers of North America registry. Patients were included if their visits occurred prior to and/or at least 6 months after publication of the ACR treatment recommendations (time periods of February 2002-June 2008 versus December 2008-December 2009). The population was divided into 2 mutually exclusive cohorts: 1) methotrexate (MTX) monotherapy users, and 2) multiple nonbiologic DMARD users. Initiation or dose escalation of biologic and nonbiologic DMARDs in response to active disease was assessed cross-sectionally and longitudinally in comparison to the ACR recommendations. The impact of the publication of the ACR recommendations on treatment practices was assessed using logistic regression, stratified by disease activity and adjusted for clustering of physicians and geographic region. RESULTS After 1 visit, 24-37% of patients receiving MTX monotherapy who had moderate disease activity and a poor prognosis or high disease activity received care consistent with the ACR recommendations; after 2 visits, 34-56% of the MTX monotherapy group received care consistent with the recommendations. In the patients receiving multiple nonbiologic DMARDs, 31-47% of those with moderate or high disease activity received care consistent with the recommendations after 1 visit, and 43-51% received such care after 2 visits. Publication of the recommendations did not significantly change treatment patterns for those with active disease. CONCLUSION Substantial numbers of RA patients with active disease did not receive care consistent with the current ACR treatment recommendations. Innovative approaches to improve care are necessary.

[1]  Maurizio Cutolo,et al.  Treating rheumatoid arthritis to target: recommendations of an international task force , 2010, Annals of the rheumatic diseases.

[2]  D. Solomon,et al.  Physician preference motivates the use of anti–tumor necrosis factor therapy independent of clinical disease activity , 2010, Arthritis care & research.

[3]  T. Pincus,et al.  RAPID3, an index to assess and monitor patients with rheumatoid arthritis, without formal joint counts: similar results to DAS28 and CDAI in clinical trials and clinical care. , 2009, Rheumatic diseases clinics of North America.

[4]  M. Wörnert,et al.  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial , 2009, The Lancet.

[5]  J. Kremer,et al.  Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. , 2009, Rheumatology.

[6]  P. Ravaud,et al.  The Gap Between Practice and Guidelines in the Choice of First-line Disease Modifying Antirheumatic Drug in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort , 2009, The Journal of Rheumatology.

[7]  J. Harrington.  The Uses of Disease Activity Scoring and the Physician Global Assessment of Disease Activity for Managing Rheumatoid Arthritis in Rheumatology Practice , 2009, The Journal of Rheumatology.

[8]  Jeffrey R Curtis,et al.  American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. , 2008, Arthritis and rheumatism.

[9]  L. Phillips,et al.  It's Time to Overcome Clinical Inertia , 2008, Annals of Internal Medicine.

[10]  S. Gabriel,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. , 2008, Arthritis and rheumatism.

[11]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. , 2007, Best practice & research. Clinical rheumatology.

[12]  B. Dijkmans,et al.  Comparison of Treatment Strategies in Early Rheumatoid Arthritis , 2007, Annals of Internal Medicine.

[13]  J. Kremer.  The CORRONA database , 2005, Annals of the rheumatic diseases.

[14]  J. Kremer,et al.  Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. , 2005, Arthritis and rheumatism.

[15]  J. Smolen,et al.  Therapeutic strategies in early rheumatoid arthritis. , 2005, Best practice & research. Clinical rheumatology.

[16]  A. McMahon,et al.  Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial , 2004, The Lancet.

[17]  Alastair Baker,et al.  Crossing the Quality Chasm: A New Health System for the 21st Century , 2001, BMJ : British Medical Journal.

[18]  M. Leavitt.  Medscape's response to the Institute of Medicine Report: Crossing the quality chasm: a new health system for the 21st century. , 2001, MedGenMed : Medscape general medicine.

[19]  P. Shekelle,et al.  Quality of care for patients with rheumatoid arthritis. , 2000, JAMA.

[20]  P. Hannonen,et al.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial , 1999, The Lancet.

[21]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[22]  S. Soraci,et al.  Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. , 1983, Arthritis and rheumatism.

[23]  Atlanta,et al.  Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. , 2008, Arthritis and rheumatism.

[24]  S. Berney.  Comparison of Treatment Strategies in Early Rheumatoid Arthritis: A Randomized Trial , 2008 .

[25]  William Branch,et al.  Clinical Inertia , 2001, Annals of Internal Medicine.